The Joint Corp. (JYNT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
Key Financial Performance
System-wide sales $129.6 million, up 2.6% year-over-year. The increase is attributed to the company's efforts to improve profitability and strengthen its digital marketing and brand campaigns.
Comp sales for all clinics opened 13 months Up 1.4% year-over-year. The increase was lower than expected due to macroeconomic headwinds and lower new patient counts, despite stable attrition and better conversions.
Revenue from continuing operations Increased 5% year-over-year to $13.3 million. This growth was mainly due to a greater number of franchised clinics in operation.
Consolidated adjusted EBITDA Grew to $3.2 million, up 52% year-over-year. The improvement is attributed to corporate cost reduction efforts and refranchising initiatives.
Unrestricted cash and equivalents $30 million as of June 30, 2025, up from $25.1 million at the end of last year. The increase was driven by proceeds from the sale of clinics and disciplined capital allocation.
Net income $93,000 compared to a net loss of $3.6 million in the same period last year. The improvement is due to refranchising efforts and cost reduction measures.
Net loss from continuing operations Improved by $720,000 to $990,000, or $0.06 per basic share, from a net loss of $1.7 million, or $0.11 per basic share, in the same period last year. The improvement is attributed to refranchising and cost reduction efforts.
Depreciation and amortization expenses Increased 18% year-over-year to $402,000. The increase was mainly due to the development of software made available for use in the first half of 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Mobile App Launch: The company launched a mobile app beta in June, which became generally available in July. Approximately 10% of active patients are already using the app. Future updates will include personalized information and gamification features to enhance patient engagement.
Refranchising Efforts: The company refranchised 37 clinics in Q2 2025, reducing corporate clinics from 13% to 8% of the portfolio. Notable transactions include selling 31 corporate clinics in Arizona and New Mexico for $11.1 million and acquiring regional developer rights in the Northwest region for $2.8 million. This region includes 46 existing franchise clinics and plans for 30 new sites.
Profitability Initiatives: The company is focusing on enhancing brand campaigns, digital marketing, dynamic revenue management, and patient-facing technology to improve profitability. A new pricing strategy with smaller, frequent price increases and a new Kickstart plan for supplemental adjustments were introduced.
Financial Performance: System-wide sales increased by 2.6% to $129.6 million, and adjusted EBITDA grew by 52% to $3.2 million compared to Q2 2024. Revenue from continuing operations rose by 5% to $13.3 million.
Strategic Shift to Pure-Play Franchisor: The company is transitioning to a pure-play franchisor model, focusing on refranchising corporate clinics and reducing general and administrative expenses. This shift is expected to increase franchise royalties and fees while improving cash flow.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Restatements: The company announced the need to restate previously issued financial statements for 2024 and Q1 2025 due to material errors in valuation methodology. This could impact investor confidence and create regulatory scrutiny.
Macroeconomic Headwinds: Lower new patient counts and softer sales trends were attributed to macroeconomic challenges, which could continue to impact revenue growth and profitability.
Refranchising Risks: The transition to a pure-play franchisor involves selling corporate clinics to franchisees. While this strategy aims to improve profitability, it carries risks such as potential operational disruptions and reliance on franchisee performance.
Marketing and Patient Acquisition Challenges: The company is pivoting its marketing strategy to focus on pain relief rather than general wellness. However, brand awareness campaigns take time to yield results, and lower new patient counts remain a concern.
Regulatory and Compliance Risks: The company faces risks related to compliance with financial reporting standards, as evidenced by the need for financial restatements.
Clinic Closures: The closure of six franchise clinics and three company-owned clinics in Q2 2025 could indicate operational challenges or underperforming locations.
Revenue Growth Uncertainty: Revised 2025 guidance reflects lower expectations for system-wide sales and comp sales growth, signaling potential challenges in achieving financial targets.
Technology Adoption Risks: The rollout of a new mobile app aims to enhance patient experience, but adoption rates and the effectiveness of the app in extending patient lifetime value remain uncertain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
System-wide sales guidance: Revised to a range of $530 million to $550 million for 2025, down from the prior guidance of $550 million to $570 million.
Comp sales growth: Expected to increase in the low single-digit range, revised from the prior guidance of mid-single-digit growth.
Consolidated adjusted EBITDA: Guidance increased to a range of $10.8 million to $11.8 million, up from the prior guidance of $10 million to $11.5 million.
New franchise clinic openings: Expected to range from 30 to 35 in 2025, compared to 57 in 2024.
Refranchising impact: As clinics shift from corporate-owned to franchise, franchise royalties and fees will increase, unallocated G&A expenses will be rationalized, and cash position will improve.
Marketing strategy: Pivoting to a pain relief-focused brand campaign to drive patient acquisition and improve long-term system-wide sales.
Dynamic revenue management: Implementing more frequent, smaller price increases and introducing new plans like the Kickstart plan to optimize pricing and patient value.
Patient-facing technology: Launched a mobile app to enhance patient experience and extend lifetime value, with future updates planned to include personalized features and gamification.
Long-term strategy: Plans to enter the next phase, Joint 3.0, in approximately 12 months, focusing on new revenue streams, additional sales channels, and growth in new markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: In June, the Board authorized a stock repurchase program under which the company may repurchase up to $5 million of our outstanding common stock through June 2027. This buyback reflects the Board's confidence in the company's long-term strategy, refranchising program, and projected cash flow generation.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the reason behind the lowered comp guidance?
A:The lowered comp guidance was due to softer recent trends, particularly in new patient acquisition. Conversion rates are up year-over-year, and attrition is in line with last year. Tougher comparables from the previous year, especially in Q4, and macroeconomic headwinds like weaker consumer sentiment also contributed. Management is addressing these headwinds by shifting marketing dollars to brand awareness, optimizing SEO, and exploring buy now, pay later options for affordability.
Q:Is the company backing off the planned broader pricing increase for the back half of the year?
A:The company is not entirely backing off but is focusing on dynamic revenue management. They have already implemented pricing actions, such as increasing walk-in prices and introducing the Kickstart plan. They will continue to optimize pricing while maintaining affordability.
Q:Can you break down the EBITDA guidance by continuing versus discontinued operations?
A:Management does not typically split out continuing and discontinued operations in their guidance. They cautioned against making assumptions due to accounting distortions, such as not recording rent or depreciation for clinics held for sale. G&A expenses are expected to improve as refranchising progresses.
Q:What is the impact of the 300 basis point change in same-store sales on traffic and pricing?
A:The change is mainly attributed to a traffic problem, particularly in new patient acquisition. Management is focusing on marketing efforts, SEO optimization, and balancing affordability in pricing. They are also testing pricing strategies to avoid sticker shock and ensure value.
Q:What are the details of the recent refranchising deals, and how do they affect sales volumes and profitability?
A:The company sold 37 clinics for $11.2 million in gross proceeds, with $2.8 million used to buy back RD territory rights in the Northwest. The 31 clinics in Arizona and New Mexico were higher performers, while the 5 Kansas City clinics were lower performers. The proceeds vary based on geography, volume, and profitability.
Q:How will recent clinic sales affect back-office expenses and long-term savings?
A:Near-term, G&A expenses may reduce as clinics transition to franchisees. Long-term savings are expected in payroll, insurance, software costs, legal fees, and travel. Management is cautious about cutting expenses too soon.
Q:How is the company testing prices in the dynamic revenue management system?
A:The company is piloting nominal price increases in certain locations to assess price elasticity. They aim to take smaller, more frequent price increases instead of significant, infrequent hikes. This approach is tested and validated with franchisees before broader implementation.
Q:How is the company leaning into its role as a pain management destination?
A:The company is shifting external messaging to focus on pain relief while educating patients on the wellness benefits of chiropractic care. They are exploring incremental products and services to enhance their role in pain management without disrupting their operating model.
Q:What is the timeline for completing the remaining corporate clinic refranchises?
A:The company aims to exit 2025 as a pure-play franchisor. They have refranchised about one-third of corporate clinics and are actively working on the remaining two-thirds.
Q:What are the plans for RD rights buybacks?
A:The company has 15 RDs covering 52% of the system, down from 16 RDs covering 57%. They will continue exploring RD buybacks based on value creation opportunities and shareholder interests.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about breaking down EBITDA guidance by continuing versus discontinued operations, citing accounting distortions and not providing specific details. Additionally, they did not provide a clear timeline or specifics on RD buybacks, stating it depends on value creation opportunities and negotiations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Barnard Alliance
Form
GA
Group LLC
Joint Ventures
LLC Research
Northwest region
Research Division
Slide term
affordability value
awareness campaign
capital allocation
care pain
change
clinic cash
confidence
income statement
increase digit
lifetime value
loss share
message
month cash
pain relief
patient count
patient pain
portfolio Slide
pricing affordability
profitability improvement
prospect
remainder
repurchase program
right Northwest
sale Comp
term profitability
term system
value patient
JYNT Transcript
The Joint Corp. (JYNT) Q1 2026 Earnings Call Transcript
Positive5-11
Despite the absence of operational and strategic updates, the financial performance shows a positive trend with revenue, net income, EBITDA, and operating margin all improving year-over-year. The company's ability to increase cash flow from operations further supports a positive outlook. The lack of concerning responses in the Q&A suggests no immediate risks were highlighted, which maintains the positive sentiment.
The Joint Corp. (JYNT) Q4 2025 Earnings Call Transcript
Unknown3-12
Despite positive full-year financial performance and optimistic marketing initiatives, the decline in comp sales and lack of specific metrics on attrition and new patient adds raise concerns. The cautious approach to pricing increases and the shift from local to national marketing may not yield immediate results. The Q&A revealed some positive signs, but uncertainties remain. Overall, the market may react neutrally over the next two weeks.
The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
The Joint Corp. (JYNT) Q2 2025 Earnings Call Transcript
Positive8-9
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
JYNT Slides
The Joint Q1 2026 slides: refranchising drives profitability surge2026-05-07
Joint Corp Q4 2025 slides: EBITDA rises 8% amid transformation push2026-03-12
The Joint Corp Q2 2025 slides: Refranchising accelerates as EBITDA jumps 52%2025-08-07
The Joint Corp Q1 2025 slides: Revenue grows 7% as franchise model expands2025-05-08
JYNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
